<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432782</url>
  </required_header>
  <id_info>
    <org_study_id>BotoxDES</org_study_id>
    <nct_id>NCT01432782</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Injection to Treat Diffuse Esophageal Spasm</brief_title>
  <acronym>Botox</acronym>
  <official_title>Prospective Randomised Double-blind Sham Study on the Use of Botox for the Treatment of Diffuse Esophageal Spasm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of botulinum toxin 100 U or saline, injected endoscopically
      in the distal esophagus, on symptoms and manometry pattern in patients with diffuse
      esophageal spasm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are selected on the basis of a clinical diagnosis of diffuse esophageal spasm, based
      on endoscopy and manometry.

      This is a sham-controlled cross-over study of injection of botulinum toxin or saline, in
      randomized order, in the distal esophagus.

      All patients have undergone esophageal manometry which shows diffuse esophageal spasm, and a
      24h pH monitoring/manometry to quantify acid reflux. All drugs prescribed to affect
      esophageal motility (nitrates, calcium antagonists) are stopped during the study. After
      randomisation, the patient will undergo standard esophageal manometry to assess baseline
      esophageal motility. On the same day the patient will be asked to fill out a set of symptom
      questionnaires including a dysphagia questionnaire. At endoscopy, the active treatment group
      receives 8 x 12.5 units, each in 0.5 ml, of botulinum toxin A which will be injected in the
      four quadrants of the esophagus at 2 and 5 cm above the lower esophageal sphincter. In the
      Sham group 8 * 0.5 ml of physiologic serum will be injected. The randomisation will be
      performed at the endoscopy unit by a nurse otherwise not involved in the protocol.

      After 1 month a stationary manometry and a new esophageal pH/manometry monitoring will be
      performed, followed by a second endoscopy with injection of saline or botulinum toxin in a
      cross-over mode. At the time of the second endoscopy each patient will fill out a dysphagia
      questionnaire. One month later, the dysphagia questionnaire is repeated.

      Subsequently, follow-up will occur at the outpatient clinic after 6 and 12 months, with
      follow-up dysphagia questionnaires but no additional manometries or endoscopies, unless the
      clinical status deteriorates.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysphagia severity score</measure>
    <time_frame>One month after treatment</time_frame>
    <description>the primary outcome variable is the symptom severity score in patients with diffuse esophageal spasm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manometry pattern</measure>
    <time_frame>One month after treatment</time_frame>
    <description>Pattern of contractions on stationary esophageal manometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Esophageal Spasm, Diffuse</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm: per-endoscopic injection of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline 4 ml</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline</description>
    <arm_group_label>Botulinum toxin</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spastic motor disorder in the upper GI tract

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Tack, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Tack, M.D., Ph.D.</last_name>
    <phone>+321634425</phone>
    <email>jan.tack@med.kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaanderen</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Tack, M.D.</last_name>
      <phone>+3216344225</phone>
      <email>jan.tack@med.kuleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <last_update_submitted>September 9, 2011</last_update_submitted>
  <last_update_submitted_qc>September 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof Dr Jan Tack</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Weight loss</keyword>
  <keyword>Dysphagia</keyword>
  <keyword>Esophageal hypermotility</keyword>
  <keyword>Chest Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Esophageal Spasm, Diffuse</mesh_term>
    <mesh_term>Esophageal Motility Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

